thiorphan has been researched along with Hypertension in 20 studies
Thiorphan: A potent inhibitor of membrane metalloendopeptidase (ENKEPHALINASE). Thiorphan potentiates morphine-induced ANALGESIA and attenuates naloxone-precipitated withdrawal symptoms.
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of prolonged administration of a carboxypeptidase Y-like kininase inhibitor, ebelactone B (EB) (2-ethyl-3, 11-dihydroxy-4, 6, 8, 10, 12-pentamethyl-9-oxo-6-tetradecenoic 1, 3-lactone), on the development of deoxycorticosterone acetate (DOCA)-salt hypertension was tested." | 7.70 | Effect of prolonged administration of a urinary kinase inhibitor, ebelactone B on the development of deoxycorticosterone acetate-salt hypertension in rats. ( Hayashi, I; Ito, H; Izumi, T; Katori, M; Majima, M; Nakajima, S, 1999) |
| "Cyclosporine (CysA), a potent immunosuppressant, is associated with hypertension and nephrotoxicity." | 7.70 | Effects of chronic neutral endopeptidase inhibition in rats with cyclosporine-induced hypertension. ( Fujimura, A; Furukawa, K; Inaba, S; Mabuchi, H; Miyamori, I; Takeda, Y, 2000) |
| "The ability of sinorphan (100 mg twice a day) to lower blood pressure was compared with that of the angiotensin converting enzyme (ACE) inhibitor captopril (25 mg twice a day) using a randomized-sequence, double-blind crossover design in 16 patients with essential hypertension." | 5.08 | Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension. ( Brouard, R; Brunner, HR; Burnier, M; Favrat, B; Lecomte, JM; Nussberger, J; Waeber, B, 1995) |
| "The effect of prolonged administration of a carboxypeptidase Y-like kininase inhibitor, ebelactone B (EB) (2-ethyl-3, 11-dihydroxy-4, 6, 8, 10, 12-pentamethyl-9-oxo-6-tetradecenoic 1, 3-lactone), on the development of deoxycorticosterone acetate (DOCA)-salt hypertension was tested." | 3.70 | Effect of prolonged administration of a urinary kinase inhibitor, ebelactone B on the development of deoxycorticosterone acetate-salt hypertension in rats. ( Hayashi, I; Ito, H; Izumi, T; Katori, M; Majima, M; Nakajima, S, 1999) |
| "Cyclosporine (CysA), a potent immunosuppressant, is associated with hypertension and nephrotoxicity." | 3.70 | Effects of chronic neutral endopeptidase inhibition in rats with cyclosporine-induced hypertension. ( Fujimura, A; Furukawa, K; Inaba, S; Mabuchi, H; Miyamori, I; Takeda, Y, 2000) |
| "DOCA-salt hypertension was induced in both BN-Ka and Brown Norway Kitasato (BN-Ki) rats after left nephrectomy." | 1.30 | Effects of a neutral endopeptidase inhibitor, BP102, on the development of deoxycorticosterone acetate-salt hypertension in kininogen-deficient Brown Norway Katholiek rats. ( Hayashi, I; Ito, H; Katori, M; Majima, M; Nakajima, S; Yajima, Y, 1998) |
| "Thiorphan was administered intravenously (i." | 1.29 | Disposition of thiorphan in DOCA-salt and spontaneously hypertensive rats. ( Berry, C; Ghai, RD; Hopkins, MF; Sakane, Y; Singh, K, 1993) |
| "Bradykinin plays a permissive role in the diuretic responses to atrial natriuretic factor and inhibitors of neutral metalloendopeptidase." | 1.28 | Neutral metalloendopeptidase inhibitors as ANF potentiators: sites and mechanisms of action. ( Chiu, PJ; Sybertz, EJ; Vemulapalli, S; Watkins, RW, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 18 (90.00) | 18.2507 |
| 2000's | 2 (10.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stanton, JL | 1 |
| Sperbeck, DM | 1 |
| Trapani, AJ | 2 |
| Cote, D | 1 |
| Sakane, Y | 3 |
| Berry, CJ | 1 |
| Ghai, RD | 4 |
| Beil, ME | 1 |
| Coté, DT | 1 |
| de Lombaert, S | 1 |
| Erion, MD | 1 |
| Gerlock, TE | 1 |
| Hopkins, MF | 2 |
| Peppard, JV | 1 |
| Webb, RL | 1 |
| Favrat, B | 1 |
| Burnier, M | 1 |
| Nussberger, J | 1 |
| Lecomte, JM | 2 |
| Brouard, R | 1 |
| Waeber, B | 1 |
| Brunner, HR | 1 |
| Pham, I | 3 |
| Lévy, B | 1 |
| Fournié-Zaluski, MC | 3 |
| Poitevin, P | 1 |
| Roques, BP | 2 |
| Michel, JB | 3 |
| Hirata, Y | 1 |
| Suzuki, Y | 1 |
| Suzuki, E | 1 |
| Hayakawa, H | 1 |
| Kimura, K | 1 |
| Goto, A | 1 |
| Omata, M | 1 |
| Minamino, N | 1 |
| Kangawa, K | 1 |
| Matsuo, H | 1 |
| Berry, C | 2 |
| Singh, K | 1 |
| Wilkins, MR | 1 |
| Gonzalez, W | 1 |
| Doucet, J | 1 |
| Wegner, M | 1 |
| Ganten, D | 1 |
| Stasch, JP | 1 |
| Vishwanatha, JK | 1 |
| Davis, RG | 1 |
| Blumberg, S | 1 |
| Gao, XP | 1 |
| Rubinstein, I | 1 |
| Nakajima, S | 2 |
| Majima, M | 2 |
| Ito, H | 2 |
| Hayashi, I | 2 |
| Yajima, Y | 1 |
| Katori, M | 2 |
| Ferro, CJ | 1 |
| Spratt, JC | 1 |
| Haynes, WG | 1 |
| Webb, DJ | 1 |
| Izumi, T | 1 |
| Pamnani, MB | 1 |
| Chen, S | 1 |
| Bryant, HJ | 1 |
| Schooley, JF | 1 |
| Haddy, FJ | 1 |
| Takeda, Y | 1 |
| Inaba, S | 1 |
| Furukawa, K | 1 |
| Fujimura, A | 1 |
| Miyamori, I | 1 |
| Mabuchi, H | 1 |
| el Amrani, AI | 1 |
| Corvol, P | 1 |
| Roques, B | 1 |
| Schulz, R | 1 |
| Ghai, R | 1 |
| Sybertz, EJ | 1 |
| Chiu, PJ | 1 |
| Watkins, RW | 1 |
| Vemulapalli, S | 1 |
| Lefrançois, P | 1 |
| Clerc, G | 1 |
| Duchier, J | 1 |
| Lim, C | 1 |
| Gros, C | 1 |
| Schwartz, JC | 1 |
1 review available for thiorphan and Hypertension
| Article | Year |
|---|---|
Clinical potential of endopeptidase-24.11 inhibitors in cardiovascular disease.
Topics: Animals; Antihypertensive Agents; Cardiovascular Diseases; Cyclohexanecarboxylic Acids; Diuretics; D | 1993 |
3 trials available for thiorphan and Hypertension
| Article | Year |
|---|---|
Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Blood Pressure; Ca | 1995 |
Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo.
Topics: Adult; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Fac | 1998 |
Antihypertensive activity of sinorphan.
Topics: Aged; Blood Pressure; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Femal | 1990 |
16 other studies available for thiorphan and Hypertension
| Article | Year |
|---|---|
Heterocyclic lactam derivatives as dual angiotensin converting enzyme and neutral endopeptidase 24.11 inhibitors.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Cysteine; Hypertension; | 1993 |
Pharmacologic profile of CGS 24128, a potent, long-acting inhibitor of neutral endopeptidase 24.11.
Topics: Amino Acid Sequence; Animals; Atrial Natriuretic Factor; beta-Alanine; Blood Pressure; Desoxycortico | 1994 |
Acute hemodynamic effects of combined inhibition of neutral endopeptidase and angiotensin converting enzyme in spontaneously hypertensive rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Drug Therapy, Combination; Enalap | 1995 |
Mechanisms underlying the augmented responses of deoxycorticosterone acetate-salt hypertensive rats to neutral endopeptidase inhibitors.
Topics: Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Base Sequence; Blood Pressure; Desoxyco | 1994 |
Disposition of thiorphan in DOCA-salt and spontaneously hypertensive rats.
Topics: Animals; Desoxycorticosterone; Hypertension; Male; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rats, S | 1993 |
Effects of angiotensin-converting enzyme and neutral endopeptidase inhibitors: influence of bradykinin.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Bradykinin; Cyclic GMP; Enalapril | 1996 |
Neutral endopeptidase inhibition potentiates the effects of natriuretic peptides in renin transgenic rats.
Topics: Animals; Animals, Genetically Modified; Atrial Natriuretic Factor; Blood Pressure; Cyclic GMP; Disea | 1996 |
Increased tissue neutral endopeptidase 24.11 activity in spontaneously hypertensive hamsters.
Topics: Animals; Anions; Chlorides; Cricetinae; Glycopeptides; Hypertension; Kidney; Neprilysin; Osmolar Con | 1998 |
Effects of a neutral endopeptidase inhibitor, BP102, on the development of deoxycorticosterone acetate-salt hypertension in kininogen-deficient Brown Norway Katholiek rats.
Topics: Administration, Oral; Animals; Atrial Natriuretic Factor; Desoxycorticosterone; Drug Administration | 1998 |
Effect of prolonged administration of a urinary kinase inhibitor, ebelactone B on the development of deoxycorticosterone acetate-salt hypertension in rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Bradykin | 1999 |
Ecadotril. (S)-acetorphan, sinorphan.
Topics: Animals; Cardiovascular Diseases; Drugs, Investigational; Endopeptidases; Heart Failure; Humans; Hyp | 1999 |
Effects of a neutral endoprotease enzyme inhibitor, thiorphan, on hemodynamics and renal excretory function in four models of experimental hypertension.
Topics: Animals; Atrial Natriuretic Factor; Biomarkers; Blood Pressure; Cyclic GMP; Hypertension; Infusions, | 2000 |
Effects of chronic neutral endopeptidase inhibition in rats with cyclosporine-induced hypertension.
Topics: Animals; Blood Pressure; Blotting, Southern; Cyclosporine; DNA Probes; Endothelin-1; Endothelium, Va | 2000 |
Effects of the selective neutral endopeptidase inhibitor, retrothiorphan, on renal function and blood pressure in conscious normotensive Wistar and hypertensive DOCA-salt rats.
Topics: Animals; Atrial Natriuretic Factor; Blood Pressure; Bradykinin; Cyclic GMP; Desoxycorticosterone; Di | 1992 |
Characterisation of neutral endopeptidase 3.4.24.11 (NEP) in the kidney: comparison between normotensive, genetically hypertensive and experimentally hypertensive rats.
Topics: Animals; Body Weight; Desoxycorticosterone; DNA; Glycopeptides; Hot Temperature; Hydrogen-Ion Concen | 1991 |
Neutral metalloendopeptidase inhibitors as ANF potentiators: sites and mechanisms of action.
Topics: Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Pressure; Bradykinin; Desoxycorti | 1991 |